British researchers have found that an experimental “Trojan-horse” cancer therapy has completely eliminated prostate cancer in experiments on mice.
The team hid cancer killing viruses inside the immune system in order to sneak them into a tumor.
Once inside, a study in the journal Cancer Research showed, tens of thousands of viruses were released to kill the cancerous cells.
Experts labeled the study “exciting,” but human tests are still needed.
Using viruses to destroy rapidly growing tumors is an emerging field in cancer therapy, however one of the challenges is getting the viruses deep inside the tumor where they can do the damage.
“There’s a problem with getting enough virus into the tumor,” said Prof. Claire Lewis from the University of Sheffield.
She leads a team which uses white blood cells as “Trojan horses” to deliver the viral punch.
British researchers have found that an experimental Trojan-horse cancer therapy has completely eliminated prostate cancer in experiments on mice
After chemotherapy or radiotherapy is used to treat cancer, there is damage to the tissue. This causes a surge in white blood cells, which swamp the area to help repair the damage.
“We’re surfing that wave to get as many white blood cells to deliver tumor-busting viruses into the heart of a tumor,” said Prof. Claire Lewis.
Her team takes blood samples and extract macrophages, a part of the immune system which normally attacks foreign invaders. These are mixed with a virus which, just like HIV, avoids being attacked and instead becomes a passenger in the white blood cell.
In the study, the mice were injected with the white blood cells two days after a course of chemotherapy ended.
At this stage each white blood cell contained just a couple of viruses. However, once the macrophages enter the tumor the virus can replicate. After about 12 hours the white blood cells burst and eject up to 10,000 viruses each – which go on to infect, and kill, the cancerous cells.
At the end of the 40-day study, all the mice who were given the Trojan treatment were still alive and had no signs of tumors.
By comparison, mice given other treatments died and their cancer had spread.
Prof. Claire Lewis said: “It completely eradicates the tumor and stops it growing back.”
She said it was a “ground-breaking” concept, but cautioned that many remarkable advances in treating mice failed to have any effect in people.
She hopes to begin human trials next year.
Vitamin B3 could be the new weapon in the fight against resistant bugs such as MRSA, a new research has suggested.
US experts found B3, also known as nicotinamide, boosts the ability of immune cells to kill Staphylococcus bacteria.
B3 increases the numbers and efficacy of neutrophils, white blood cells that can kill and eat harmful bugs.
The study, in the Journal of Clinical Investigation, could lead to a “major change in treatment”.
Vitamin B3 was tested on Staphylococcal infections, such as the potentially fatal MRSA (Methicillin-resistant Staphylococcus aureus).
Vitamin B3 was tested on Staphylococcal infections, such as the potentially fatal MRSA
Such infections are found in hospitals and nursing homes, but are also on the rise in prisons, the military and among athletes.
The scientists used extremely high doses of B3 – far higher than that obtained from dietary sources – in their tests, carried out both on animals and on human blood.
And the researchers say there is as yet no evidence that dietary B3 or supplements could prevent or treat bacterial infections.
The researchers say B3 appears to be able to “turn on” certain antimicrobial genes, boosting the immune cells’ killing power.
Prof. Adrian Gombart, of Oregon State University’s Linus Pauling Institute, who worked on the research, said: “This is potentially very significant, although we still need to do human studies.
“Antibiotics are wonder drugs, but they face increasing problems with resistance by various types of bacteria, especially Staphylococcus aureus.
“This could give us a new way to treat Staph infections that can be deadly, and might be used in combination with current antibiotics.
“It’s a way to tap into the power of the innate immune system and stimulate it to provide a more powerful and natural immune response.”
Prof. Mark Enright, of the University of Bath, said: “Neutrophils are really the front line against infections in the blood and the use of nicotinamide seems safe at this dose to use in patients as it is already licensed for use.
“This could cause a major change in treatment for infections alongside conventional antibiotics to help bolster patients immune system.
“I would like to see in patient clinical trials but cannot see why this couldn’t be used straight away in infected patients.”
[googlead tip=”patrat_mediu” aliniat=”stanga”]A new treatment for leukemia had amazing results, surprising even the researchers who designed it. The new treatment has eradicated the cancer cells present in the first three patients tested bodies.
Early results of a clinical trial showed that genetically engineered T cells eradicate leukemia cells and thrive.
Scientists from the University of Pennsylvania have genetically engineered patients’ T cells — a type of white blood cell — to attack cancer cells in advanced cases of a common type of leukemia.
The first two of three patients studied, who received the innovative treatment, have been cancer-free for more than one year. In the case of the third patient, over 70% of cancer cells were removed, according to the researchers.
"Microscopic image showing two T cells binding to beads, depicted in yellow, that cause the cells to divide. After the beads are removed, the T cells are infused into cancer patients." (Dr. Carl June / Pennsylvania Medicine)
“In just three weeks, tumors were destroyed, the effect being more violent than we ever have imagined,” said Dr. Carl June, one of the researchers involved in the study.
“Each cell can destroyed thousands of cancer cells,” said June, “each patient have been removed tumors from at least 900 grams.”
“A huge accomplishment”
[googlead tip=”vertical_mare” aliniat=”dreapta”] “This is a huge accomplishment — huge,” said Dr. Lee M. Nadler, dean for clinical and translational research at Harvard Medical School, who discovered the molecule on cancer cells that the Pennsylvania team’s engineered T cells target.
Innovative treatment is using patients’ own T cells, which are extracted from body cells and then genetically modified to attack cancer cells and to multiply and then reintroduced into patients’ blood.
Findings of the trial were reported Wednesday in the New England Journal of Medicine and Science Translational Medicine.
According to LA Times report, for building the cancer-attacking cells, the researchers modified a virus to carry instructions for making a molecule that binds with leukemia cells and directs T cells to kill them. Then they drew blood from three patients who suffered from chronic lymphocytic leukemia and infected their T cells with the virus.
When they infused the blood back into the patients, the engineered T cells successfully eradicated cancer cells, multiplied to more than 1,000 times in number and survived for months. They even produced dormant “memory” T cells that might spring back to life if the cancer was to return.
On average, the team calculated, each engineered T cell eradicated at least 1,000 cancer cells.
Side effects included loss of normal B cells, another type of white blood cell, which are also attacked by the modified T cells, and tumor lysis syndrome, a complication caused by the breakdown of cancer cells.
“We knew [the therapy] could be very potent,” said Dr. David Porter, director of the blood and marrow transplantation program at the Hospital of the University of Pennsylvania in Philadelphia and a coauthor of both papers, which were published in the New England Journal of Medicine and Science Translational Medicine.
“But I don’t think we expected it to be this dramatic on this go-around.”
Bone marrow transplants from healthy donors have been effective in fighting some cancers, including chronic lymphocytic leukemia, but the treatment can cause side effects such as infections, liver and lung damage, even death.
“1/5 of bone marrow transplant recipients may die of complications unrelated to their cancer,” Porter said.
Researchers have been working for many years to develop cancer treatments that leverage a patient’s immune system to kill tumors with much greater precision.
Specialists not involved in the trial said the new discovery is very important because it suggested that T cells could be adapted to destroy a range of cancer cells, including ones of the blood, breast or colon
“It is kind of a holy grail,” said Dr. Gary Schiller, a researcher from UCLA’s Jonsson Comprehensive Cancer Center who was not involved in the trial.
“It would be great if this could be applied to acute leukemia, where there is a terrible unmet medical need,” UCLA’s Schiller said.
Dr. David Porter added:
“Previously efforts to replace risky bone marrow transplants with such engineered T cells proved disappointing because the cells were unable to multiply or survive in patients.”
“This time, the T cells were more robust because the team added extra instructions to their virus to help the T cells multiply, survive and attack more aggressively.”
“About 15,000 patients are diagnosed with chronic lymphocytic leukemia every year. Many can live with the disease for years. Bone marrow transplants are the only treatment that eradicates the cancer.”
[googlead tip=”lista_mare” aliniat=”stanga”]Dr. David Porter cautioned that these were preliminary results and the scientists plan to continue the trial, treating more patients and following them over longer periods.
“The researchers also would like to expand the work to other tumor types and diseases,” Porter said.
The hope, scientists said, is that the method would work for cancers that can kill more ruthlessly and rapidly.